Basis: Trailing twelve months (TTM), to the latest fiscal quarter end. Source: stored company filings and market data; unavailable inputs remain N/A.
Is the return on equity (ROE) high or low?
The return on equity (ROE) of -136.82% is in line with its 5-year average of -125.24%, near the high end of its 5-year range (-831.31%–-27.61%).
As of the fiscal period ended Tuesday, June 30, 2026. 0.77% above its 12-month average of -137.88%.
Trailing-twelve-month return on equity at each fiscal quarter end; no daily interpolation. Q2 FY2026 (2026-06-30): -136.82%.
RETURN ON EQUITY (ROE)
-136.82%
RETURN ON EQUITY (ROE) AVG TTM
-137.88%
RETURN ON EQUITY (ROE) AVG 3Y
-224.31%
RETURN ON EQUITY (ROE) AVG 5Y
-125.24%
RETURN ON EQUITY (ROE) AVG 10Y
N/A
RETURN ON EQUITY (ROE) AVG 15Y
N/A
RETURN ON EQUITY (ROE) AVG 20Y
N/A
CURRENT VS TTM AVG
+0.77%
CURRENT VS 3Y AVG
+39.01%
CURRENT VS 5Y AVG
-9.25%
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
-42.01%
median of 754 covered companies
CURRENT VS SECTOR MEDIAN
-225.68%
vs the sector median at left
RenovoRx, Inc.
Market Cap
$62.62M
Return on Equity (ROE)
-136.82%
TTM Avg
-137.88%
3Y Avg
-224.31%
5Y Avg
-125.24%
Market Cap
$62.78M
Return on Equity (ROE)
-492.89%
TTM Avg
-50.27%
3Y Avg
-279.07%
5Y Avg
-249.48%
Market Cap
$63.02M
Return on Equity (ROE)
-8.80%
TTM Avg
-13.04%
3Y Avg
-7.69%
5Y Avg
-7.21%
Market Cap
$63.78M
Return on Equity (ROE)
-62.81%
TTM Avg
-75.79%
3Y Avg
-56.25%
5Y Avg
-48.09%
Market Cap
$64.18M
Return on Equity (ROE)
N/A
TTM Avg
140.07%
3Y Avg
68.30%
5Y Avg
45.41%
Market Cap
$60.42M
Return on Equity (ROE)
N/A
TTM Avg
-866.00%
3Y Avg
-422.47%
5Y Avg
-312.54%
Market Cap
$60.02M
Return on Equity (ROE)
N/A
TTM Avg
85.37%
3Y Avg
6.44%
5Y Avg
-23.00%
Market Cap
$65.85M
Return on Equity (ROE)
-35.13%
TTM Avg
-26.80%
3Y Avg
-19.63%
5Y Avg
-14.70%
Market Cap
$65.86M
Return on Equity (ROE)
-122.71%
TTM Avg
-558.46%
3Y Avg
-307.41%
5Y Avg
-314.14%
| NAME | MARKET CAP | RETURN ON EQUITY (ROE) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| RenovoRx, Inc. (RNXT) | $62.62M | -136.82% | -137.88% | -224.31% | -125.24% |
| Heron Therapeutics, Inc. (HRTX)vs › | $62.78M | -492.89% | -50.27% | -279.07% | -249.48% |
| InterCure Ltd. (INCR)vs › | $63.02M | -8.80% | -13.04% | -7.69% | -7.21% |
| Pliant Therapeutics, Inc. (PLRX)vs › | $63.78M | -62.81% | -75.79% | -56.25% | -48.09% |
| Alps Group Inc (ALPS)vs › | $64.18M | N/A | 140.07% | 68.30% | 45.41% |
| Fractyl Health, Inc. (GUTS)vs › | $60.42M | N/A | -866.00% | -422.47% | -312.54% |
| Oncolytics Biotech Inc. (ONCY)vs › | $60.02M | N/A | 85.37% | 6.44% | -23.00% |
| XBiotech Inc. (XBIT)vs › | $65.85M | -35.13% | -26.80% | -19.63% | -14.70% |
| Cingulate Inc. (CING)vs › | $65.86M | -122.71% | -558.46% | -307.41% | -314.14% |
| Gossamer Bio, Inc. (GOSS)vs › | $65.87M | N/A | -26.44% | -559.66% | -417.87% |
ROE
-136.8%
ROA
-107.1%
ROE = Net Income / Total Shareholders' Equity
Return on equity measures how efficiently a company generates profit from shareholders' equity. Higher ROE indicates better capital efficiency.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | RETURN ON EQUITY (ROE) |
|---|---|
| 2026-06-30 | -136.82% |
| 2026-03-31 | -108.91% |
| 2025-12-31 | -205.98% |
| 2025-09-30 | -137.47% |
| 2025-06-30 | -100.22% |
| 2025-03-31 | -77.21% |
| 2024-12-31 | -196.83% |
| 2024-09-30 | -129.59% |
| 2024-06-30 | -87.50% |
| 2024-03-31 | -455.63% |
| 2023-06-30 | -831.31% |
| 2023-03-31 | -311.52% |
| 2022-12-31 | -160.46% |
| 2022-09-30 | -123.81% |
| 2022-06-30 | -93.51% |
| 2022-03-31 | -65.22% |
| 2021-12-31 | -41.20% |
| 2021-09-30 | -27.61% |
